Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy by unknown
POSTER PRESENTATION Open Access
Genetic engineering of T cells with receptors from
NY-ESO-1-specific tumor-recognizing CD4+ T cell
as a novel approach for adoptive T cell therapy
Junko Matsuzaki1*, Takemasa Tsuji1, Immanuel Luescher2, Hiroshi Shiku3, Junichi Mineno4, Sachiko Okamoto4,
Lloyd Old5, Protul Shrikant6, Sacha Gnjatic7, Kunle Odunsi1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Background
Tumor antigen-specific CD4+ T cells generally orches-
trate and regulate innate and adaptive immune cells to
provide immune surveillance against malignancy. How-
ever, activation of antigen-specific CD4+ T cells is
restricted at local tumor sites where antigen-presenting
cells are frequently dysfunctional, which can cause rapid
exhaustion of anti-tumor immune responses. Herein, we
characterize anti-tumor effects of a unique human CD4+
helper T cell subset that directly recognizes the cyto-
plasmic tumor antigen, NY-ESO-1, presented by MHC
class II (MHC-II) on cancer cells. In addition, we clone
the TCR gene from tumor-recognizing CD4+ T cells
(TR-CD4) and test the function of TCR gene-engineered
cells.
Methods
NY-ESO-1-specfic CD4+ or CD8+ T cells were obtained
from ovarian cancer patients who received NY-ESO-1
vaccine. Full-length TCR a and b chain genes of TR-
CD4 were cloned by 5’ RACE PCR. TCR gene was
transduced into activated T cells by MSCV-based retro-
viral vector. The effector function was evaluated against
cognate peptide-pulsed target cells or NY-ESO-1+MHC-
II+ cancer cell lines by ELISA, intracellular cytokine
staining or CTL assay.
Results
TR-CD4, but not conventional NY-ESO-1-specific CD4+
T cells, directly recognized cancer cells in MHC-II-
dependent and NY-ESO-1-specific manners. Presentation
of intracellular NY-ESO-1 on MHC-II by cancer cells
required non-classical MHC-II antigen presentation
mechanisms. Upon direct recognition of cancer cells,
TR-CD4 potently induced IFN-g-dependent growth
arrest in cancer cells. In addition, direct recognition
of cancer cells triggers TR-CD4 to provide help to
NY-ESO-1-specific CD8+ T cells by enhancing cytotoxic
activity, and improving viability and proliferation. Nota-
bly, the TR-CD4 either alone or in combination with
NY-ESO-1-specific CD8+ T cells significantly inhibited
tumor growth in vivo in a xenograft model. Finally, retro-
viral gene-engineering of polyclonally activated T cells
with TCR derived from TR-CD4 successfully produced
large numbers of functional TR-CD4.
Conclusions
These observations provide mechanistic insights into the
role of TR-CD4 in tumor immunity, and suggest that
approaches to utilize TR-CD4 will augment anti-tumor
immune responses for durable therapeutic efficacy in
cancer patients. Large numbers of TR-CD4 that directly
recognize cancer cells and enhance CD8+ T cell func-
tions can be generated by gene-engineering with TCR
from TR-CD4. Antigen-presenting cell-independent pro-
vision of CD4-help by TR-CD4 is especially important
to enhance durable CD8+ T cell anti-tumor functions at
the tumor local site. Adoptive T cell therapy using TR-
CD4 in combination with CD8+ T cells could be a pro-
mising strategy for effective eradication of tumors.
Authors’ details
1Roswell Park Cancer Institute, Buffalo, NY, USA. 2Ludwig Center for Cancer
Research, Epalinges, Switzerland. 3Mie University Graduate School of
Medicine, Tsu, Japan. 4TAKARA BIO INC, Otsu, Japan. 5Ludwig Institute for
1Roswell Park Cancer Institute, Buffalo, NY, USA
Full list of author information is available at the end of the article
Matsuzaki et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P34
http://www.immunotherapyofcancer.org/content/3/S2/P34
© 2015 Matsuzaki et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cancer Research, New York, NY, USA. 6Mayo Clinic, Scottsdale, AZ, USA.
7MSSM, New York, NY, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P34
Cite this article as: Matsuzaki et al.: Genetic engineering of T cells with
receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a
novel approach for adoptive T cell therapy. Journal for ImmunoTherapy of
Cancer 2015 3(Suppl 2):P34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Matsuzaki et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P34
http://www.immunotherapyofcancer.org/content/3/S2/P34
Page 2 of 2
